Biotech Calendar: Key Dates and Events

BOSTON, Mass. (TheStreet) --The dog days of August are here. Nothing of much importance is going on. It's hot and humid in Boston, and I'm getting ready for a much-needed vacation. The rest will come in handy because the biotech sector gets back to business in September.

To get you ready, I've put together a calendar of September biotech events. Enjoy.

Aug. 24
U.S. Food and Drug Administration's responds to Cell Therapeutics'(CTIC) priority review request for pixantrone as a treatment for non-Hodgkin's lymphoma.

Sept. 1
The Oncologic Drug Advisory Committee of the Food and Drug Administration meets to review Genzyme's(GENZ) Clolar and Vion Pharmaceuticals'(VION.OB) Onrigin, both as a treatment for acute myeloid leukemia.

Sept. 2
The same FDA advisory committee meets to review Allos Therapeutics'(ALTH) pralatrexate for peripheral T-cell lymphoma.
FDA approval decision date for Endo Pharmaceuticals'(ENDP) Nebido, a long-acting testosterone replacement therapy.

Sept. 7
FDA approval decision date for Spectrum Pharmaceuticals'(SPPI) Zevalin, a drug for non-Hodgkin's lymphoma.

Sept. 9-10
Robert W. Baird Small Cap Health Care Conference

Sept. 9-11
Thomas Weisel Partners Healthcare Conference (Boston) and the Rodman & Renshaw 11th Annual Healthcare Conference (New York City)

Sept. 11-15
American Society for Bone and Mineral Research (ASBMR)

Sept. 12-15
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Sept. 13-15
American College of Clinical Pharmacology (ACCP)

Sept. 14-15
Morgan Stanley Healthcare Unplugged Conference

Sept. 16
The 16th Annual NewsMakers in the Biotech Industry, sponsored by BioCentury.
The Arthritis Drugs Advisory Committee of the FDA will review Auxilium Pharmaceutical's(AUXL) Xiaflex for advanced Dupuytren's disease, a condition in which the tendons of the hand that help move the fingers of the hand become thickened and scarred.
FDA approval decision date for Theravance's(THRX) antibiotic Telavancin.